HCW Biologics (NASDAQ:HCWB) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of HCW Biologics (NASDAQ:HCWB – Free Report) from a sell rating to a hold rating in a research report report published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a report on Thursday, October 15th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $30.00.

Get Our Latest Report on HCW Biologics

HCW Biologics Stock Performance

Shares of NASDAQ HCWB opened at $1.12 on Friday. The company has a market cap of $2.51 million, a P/E ratio of -0.04 and a beta of 2.41. The firm’s fifty day moving average is $1.90 and its two-hundred day moving average is $4.13. HCW Biologics has a 52-week low of $1.09 and a 52-week high of $23.94.

HCW Biologics (NASDAQ:HCWB – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($11.58) EPS for the quarter, missing the consensus estimate of ($1.98) by ($9.60). HCW Biologics had a negative return on equity of 262.33% and a negative net margin of 83.03%. The company had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.14 million.

About HCW Biologics

(Get Free Report)

HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic inflammation, immune dysfunction and aging. The company’s research is intended to address conditions in which persistent inflammation contributes to disease progression.

HCW Biologics uses its proprietary TOBI platform to design multifunctional fusion proteins that can target inflammatory pathways and modify immune responses. Its development programs have included HCW9218, an investigational immunotherapy designed to combine immune-stimulating activity with inhibition of transforming growth factor beta, a signaling pathway associated with immune suppression and disease progression.

Further Reading